274 related articles for article (PubMed ID: 30550753)
1. Plecanatide for Treatment of Chronic Constipation and Irritable Bowel Syndrome.
Love BL
Am J Med; 2019 May; 132(5):572-575. PubMed ID: 30550753
[TBL] [Abstract][Full Text] [Related]
2. Plecanatide for the treatment of constipation-predominant irritable bowel syndrome.
Miner PB
Expert Rev Gastroenterol Hepatol; 2020 Feb; 14(2):71-84. PubMed ID: 31985305
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome.
Miner PB
Expert Opin Pharmacother; 2018 Feb; 19(2):177-183. PubMed ID: 29376436
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Tolerability of Guanylate Cyclase-C Agonists for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation: A Systematic Review and Meta-Analysis.
Shah ED; Kim HM; Schoenfeld P
Am J Gastroenterol; 2018 Mar; 113(3):329-338. PubMed ID: 29380823
[TBL] [Abstract][Full Text] [Related]
5. Plecanatide: First Global Approval.
Al-Salama ZT; Syed YY
Drugs; 2017 Apr; 77(5):593-598. PubMed ID: 28255961
[TBL] [Abstract][Full Text] [Related]
6. Plecanatide for the treatment of chronic idiopathic constipation in adult patients.
Bassotti G; Usai Satta P; Bellini M
Expert Rev Clin Pharmacol; 2019 Nov; 12(11):1019-1026. PubMed ID: 31575291
[No Abstract] [Full Text] [Related]
7. Evaluation of Plecanatide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation in Patients 65 Years or Older.
Menees SB; Franklin H; Chey WD
Clin Ther; 2020 Jul; 42(7):1406-1414.e4. PubMed ID: 32660770
[TBL] [Abstract][Full Text] [Related]
8. Plecanatide for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation: Post hoc analyses of placebo-controlled trials in adults with severe constipation.
Cash BD; Sharma A; Walker A; Laitman AP; Chang L
Neurogastroenterol Motil; 2023 Sep; 35(9):e14632. PubMed ID: 37332239
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials.
Brenner DM; Fogel R; Dorn SD; Krause R; Eng P; Kirshoff R; Nguyen A; Crozier RA; Magnus L; Griffin PH
Am J Gastroenterol; 2018 May; 113(5):735-745. PubMed ID: 29545635
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Acid Suppression Therapy on the Safety and Efficacy of Plecanatide: Analysis of Randomized Phase III Trials.
Moshiree B; Schoenfeld P; Franklin H; Rezaie A
Clin Ther; 2022 Jan; 44(1):98-110.e1. PubMed ID: 35086735
[TBL] [Abstract][Full Text] [Related]
11. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
Gale JD
Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
[TBL] [Abstract][Full Text] [Related]
12. Benefit-Risk Assessment of Plecanatide in the Treatment of Chronic Idiopathic Constipation.
Miner PB
Drug Saf; 2019 May; 42(5):603-615. PubMed ID: 30649746
[TBL] [Abstract][Full Text] [Related]
13. New pharmacological treatment options for irritable bowel syndrome with constipation.
Nusrat S; Miner PB
Expert Opin Emerg Drugs; 2015; 20(4):625-36. PubMed ID: 26548544
[TBL] [Abstract][Full Text] [Related]
14. Guanylate cyclase C agonists: emerging gastrointestinal therapies and actions.
Camilleri M
Gastroenterology; 2015 Mar; 148(3):483-7. PubMed ID: 25576859
[No Abstract] [Full Text] [Related]
15. A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation.
Miner PB; Koltun WD; Wiener GJ; De La Portilla M; Prieto B; Shailubhai K; Layton MB; Barrow L; Magnus L; Griffin PH
Am J Gastroenterol; 2017 Apr; 112(4):613-621. PubMed ID: 28169285
[TBL] [Abstract][Full Text] [Related]
16. Plecanatide Improves Abdominal Bloating and Bowel Symptoms of Irritable Bowel Syndrome with Constipation.
Brenner DM; Sharma A; Rao SSC; Laitman AP; Heimanson Z; Allen C; Sayuk GS
Dig Dis Sci; 2024 May; 69(5):1731-1738. PubMed ID: 38594429
[TBL] [Abstract][Full Text] [Related]
17. Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases.
Jarmuż A; Zielińska M; Storr M; Fichna J
Neurogastroenterol Motil; 2015 Aug; 27(8):1057-68. PubMed ID: 25930667
[TBL] [Abstract][Full Text] [Related]
18. New pharmacological treatment options for chronic constipation.
Corsetti M; Tack J
Expert Opin Pharmacother; 2014 May; 15(7):927-41. PubMed ID: 24661106
[TBL] [Abstract][Full Text] [Related]
19. Drugs for Irritable Bowel Syndrome.
Med Lett Drugs Ther; 2020 Mar; 62(1594):25-32. PubMed ID: 32324172
[No Abstract] [Full Text] [Related]
20. Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.
Vazquez Roque M; Camilleri M
Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):301-10. PubMed ID: 21651347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
